Author/Editor
Ernie Tremblay
Publisher
Money Map Press
Description
Newsletter/trading service that aims to track important trading catalyst dates for biotech stocks, including FDA approvals and submissions and clinical trial data releases. Formerly called BioScience Millionaire.
Newsletter is no longer active.
Overall Rating
Rating: 1.3/5. From 7 votes.
Please wait...
1.3
Rating from 34 votes
If you’ve subscribed to Biotech Insider Alert (defunct), please click the stars below to indicate your rating for this newsletter, and please share any other feedback about your experience using the comment box below.
Investment Performance
Rating from 11 votes
Rating: 1.4/5. From 11 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 1 Votes
- 2 Stars 2 Votes
- 1 Stars 8 Votes
Quality Of Writing/Analysis
Rating from 9 votes
Rating: 1.6/5. From 9 votes.
Please wait...
Your vote
- 5 Stars 1 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 1 Votes
- 1 Stars 7 Votes
Value For Price
Rating from 7 votes
Rating: 1.0/5. From 7 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 0 Votes
- 1 Stars 7 Votes
Customer Service
Rating from 7 votes
Rating: 1.3/5. From 7 votes.
Please wait...
Your vote
- 5 Stars 0 Votes
- 4 Stars 0 Votes
- 3 Stars 0 Votes
- 2 Stars 2 Votes
- 1 Stars 5 Votes
Have u duped everyone who has relied on Money Market Press as a valid source of info and pays handsomely for it. When r the hedge funds coming in to raise the price into the $20’s as u say?
did anyone figure out what Ernie T. is talking about? ”
“a new, highly infectious strain of “Old Man’s Friend” is quietly sweeping the heartland, killing nearly every 10 minutes. The FDA’s DOUBLE-SHOT FINAL DECISION is expected on December 27 and December 28. this tiny company’s CEO has been summoned to a critical meeting with the FDA on November 4. this tiny $27 million company. We’d be looking at revenues of $1.8 billion, a sales surge of 6,600%. If the stock follows, that’d be good enough to turn $10,000 into $660,000.”
This interests me too, since it looks like the latest all in push by the Money Map Press stable.
Ruth
Well, What is their record for past recommendations?
Money Map Press will tout their “great record” for making money for their subscribers. But that is not my personal experience.From my experience their prime objective is to make money from new subscribers. I fell big time for the hype and lies to the tune of over $8,000. To add injury to insult I also lost thousands of dollars thanks to their recommendations.
Biotech Insider is another one of the Money Map Press failures. Fell for the big hype that a biotech stock was set to “explode”. The expectation was that there would be a lot of large pharmaceutical companies lining up to get the technology and patents. The results so far? The $5,000 that I invested in stock is now worth $2,000. Unfortunately, I have followed the recommendations of other Money Map Press services and have lost thousands of dollars. Don’t believe any of the Money Map hype for any of their services. Money Map Press gets your money and you lose.
Biotech insider alert/Ernie Tremblay. He is hawking the next pharmaceutical cannabis. Any ideas what it may be?
Fradulant charges by Dylan Jovine on Biotech insider this evening 10/2/23 charged $349.00 plus $39.00 . Did not order enrollment.
This company has many fraud current lawsuits as I now determined online. I want full refund.
This evening, Dylan Jovine sent bill for membership for $349.00 plus 39.00 on 2/1/23 that I did not request or check. Requested refund with no response.
Fraud is prevalent with this company currently as I now determined.